Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis

Status Not yet recruiting

Clinical Trial Summary

Primary osteoarthritis is a debilitating disease characterized by extensive damage to the joints and excruciating pain leading to loss of activity and depression. Despite advances in diagnosis, the quest for the development of a disease-modifying osteoarthritis drug has proven unsuccessful. Human cartilage only has limited regenerative potential. Transplantation is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. The acquisition of MSC does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. The investigators inject allogeneic human mesenchymal stem cells to the cartilage lesions in patients via intra-articular injection method, and to investigate the efficacy and safety.

Clinical Trial Description

Osteoarthritis is one of the commonest diseases in the world, with a global disease burden of 83%. Plain radiograph remained the main modality in diagnosing osteoarthritis. Chondrogen is a mesenchymal stem cell-derived from umbilical cord tissue product. The mesenchymal stem cell is used for the study because of its ability to proliferate and differentiate into various tissues such as chondrocytes, adipocytes, and osteocytes. Various clinical studies have been conducted for arthritis, orthopedic, joint, and cartilage.

This study will enroll 100 patients age 30-70 years old. They will be divided into 2 groups which are the group which will receive the investigational drug (ChondrogenTM and HA) and another group will receive a placebo (saline and HA). It will be a randomized double-blinded study where the participants and the investigator would not know what are the things being received. This study will be conducted for 24 months. The injection will be given on the baseline day after screening the volunteers. The patients will be assessed on VAS, WOMAC, IKDC, KOOS PROMIS29, the interleukins, and MRI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04520945
Study type	Interventional
Source	Meluha Life Sciences SDN BHD
Contact	Prakash Nathan, MBA
Phone	03-88902968
Email	research@meluhalifesciences.com
Status	Not yet recruiting
Phase	Phase 2
Start date	October 31, 2020
Completion date	September 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03895489` - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses	N/A
Completed	`NCT03660943` - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain	Phase 3
Completed	`NCT04531969` - Comparison of Outpatient and Inpatient Spa Therapy	N/A
Completed	`NCT02848027` - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment	Phase 3
Completed	`NCT05160246` - The Instant Effect of Kinesiology Taping in Patients With Knee OA	N/A
Recruiting	`NCT06080763` - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed	`NCT03643588` - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain	N/A
Active, not recruiting	`NCT05100225` - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis	Phase 2
Active, not recruiting	`NCT04061733` - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis	N/A
Completed	`NCT04051489` - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting	`NCT05546541` - Epidemiology and Nutrition
Recruiting	`NCT05447767` - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg	Phase 2
Not yet recruiting	`NCT04448106` - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis	Phase 2
Not yet recruiting	`NCT03225911` - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis	N/A
Completed	`NCT05070871` - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women	N/A
Completed	`NCT05703087` - Positive Cueing in Knee Arthroplasty.	N/A
Not yet recruiting	`NCT06042426` - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population	Phase 4
Not yet recruiting	`NCT02826850` - Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial	Phase 3
Terminated	`NCT02615522` - Prospective Post Market Clinical Follow-Up of the Primary Knee Endoprosthesis BPK-S Integration
Completed	`NCT03037489` - A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.